Johnson & Johnson (J&J) announced robust second-quarter (Q2) revenues totaling approximately $25.3 billion, marking a significant 6.6% increase year-over-year (YoY). The company’s MedTech division, J&J MedTech, emerged as a substantial contributor, accounting for over one-third of this impressive total with revenues of around $8.93 billion, a 4.5% YoY uplift. This strong performance from the MedTech segment was largely propelled by its burgeoning cardiovascular portfolio, notably the revolutionary Shockwave intravascular lithotripsy (IVL) system. The remaining revenue, approximately $16.4 billion, was generated by J&J’s pharmaceutical products, now operating under the Innovative Medicine business segment.
This financial disclosure comes as J&J raises its full-year earnings per share (EPS) guidance for 2026. The company now anticipates earnings to fall within the $11.60 to $11.75 per share range, an upward revision from its previous projection of $11.45 to $11.65 per share. This positive outlook signals continued confidence in the company’s strategic direction and product pipeline, even as the broader market reacts to the nuances of its quarterly performance.
Despite the overall positive financial trajectory and the increased full-year outlook, J&J’s stock experienced a slight dip, trading down approximately 1.5% at $250.09 on the Nasdaq in early trading on July 15, following a prior close of $253.85. This market reaction is attributed, in part, to J&J MedTech’s Q2 revenues of $8.93 billion falling just shy of analysts’ average estimate of $8.97 billion, according to data compiled by the London Stock Exchange Group (LSEG) and reported by Reuters. This marginal miss, while not indicative of a significant underperformance, highlights the market’s keen attention to precise revenue targets. J&J maintains a substantial market capitalization of around $611 billion, underscoring its position as a titan in the global healthcare industry.
Cardiovascular Innovations Fueling MedTech Momentum
The significant growth within J&J MedTech during the second quarter was primarily driven by key segments, with electrophysiology products and the Shockwave intravascular lithotripsy (IVL) system playing pivotal roles. The Shockwave IVL system, a cornerstone of J&J’s cardiovascular disease offerings, has proven to be a strategic acquisition and a powerful revenue generator.
Johnson & Johnson finalized its acquisition of Shockwave Medical in June 2024 for a substantial $13.1 billion. This strategic move integrated Shockwave’s innovative IVL catheter technology into J&J’s expansive portfolio, particularly enhancing its capabilities in treating a range of vascular pathologies, including peripheral artery disease (PAD). The IVL technology represents a significant advancement in interventional cardiology, utilizing sonic pressure waves to fracture calcium deposits within arteries, thereby facilitating the delivery of subsequent treatments and improving blood flow.
Shockwave Medical’s pioneering role in the IVL market dates back to 2017 with the European launch of its IVL system for PAD treatment, following its receipt of CE mark approval in 2015. In the United States, the company achieved a significant milestone in 2016 by becoming the first to receive U.S. Food and Drug Administration (FDA) approval for an IVL system targeting PAD. The commercial launch of its first IVL catheter in the US in 2021 further cemented its market leadership and paved the way for broader adoption. The integration of Shockwave’s technology allows J&J MedTech to offer a comprehensive suite of solutions for complex cardiovascular interventions, addressing a critical unmet need in patient care.
Beyond its cardiovascular success, J&J MedTech also saw contributions from its vision care and orthopaedics segments. The strong performance in contact lenses, a segment where J&J has long held a dominant position, is further bolstered by the company’s recent commitment to expand its manufacturing capabilities. In a significant investment, J&J announced plans to allocate $1.1 billion to strengthen its vision manufacturing operations in Florida. This strategic investment is poised to enhance production capacity, drive innovation in contact lens technology, and ensure a stable supply chain for its popular ACUVUE® brand, catering to the growing global demand for advanced vision correction solutions. The trauma segment within orthopaedics also demonstrated resilience, contributing to the overall robust performance of the MedTech division.
Pharma Business Continues to Rely on Established Growth Drivers
In its pharmaceutical segment, J&J’s Innovative Medicine business, the company reported consistent performance driven by its established blockbuster drugs. These core products, which have been instrumental in the segment’s growth in previous quarters, continue to anchor its revenue streams.
In the oncology space, key contributors include Darzalex® (daratumumab), a widely used treatment for multiple myeloma; Carvykti® (ciltacabtagene autoleucel), a CAR-T therapy for relapsed or refractory multiple myeloma; Tecvayli® (teclistamab-cqyv), another innovative treatment for multiple myeloma; and the combination of Rybrevant® (amivantamab) and Lazcluze® (lazertinib), which target specific mutations in non-small cell lung cancer. These therapies represent J&J’s commitment to advancing cancer care through targeted and innovative treatment modalities.
The immunology portfolio continues to be driven by Tremfya® (guselkumab), a highly effective treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis, alongside other established immunology products. In neuroscience, Spravato® (esketamine) nasal spray, indicated for treatment-resistant depression and depressive symptoms in adults with major depressive disorder, remains a significant growth driver. Furthermore, Calypta® (lumateperone), also within the neuroscience segment, has emerged as a notable growth driver following J&J’s substantial $14.6 billion acquisition of Intra-Cellular Therapies in April 2025. This acquisition significantly bolsters J&J’s neuroscience pipeline and market presence, particularly in addressing complex neurological and psychiatric conditions.
Strategic Vision and Future Outlook
Joaquin Duato, CEO of Johnson & Johnson, expressed optimism regarding the company’s financial performance and strategic direction. "With raised guidance and quarterly sales surpassing $25bn, we are on track to meet our 2026 target of more than $100bn in annual revenue for the first time in our Company’s 140-year history," Duato stated. This ambitious target underscores J&J’s long-term growth strategy and its confidence in its diversified business model, encompassing both innovative medicines and cutting-edge medical technologies.
The company’s strategic focus on high-growth areas, such as cardiovascular intervention through the Shockwave acquisition and advanced oncology and neuroscience treatments, positions it well for continued expansion. The significant investment in vision care manufacturing further demonstrates a commitment to strengthening core businesses and adapting to evolving market demands.
Market Context and Analyst Expectations
The Q2 earnings report and subsequent stock performance reflect a dynamic market environment where investor expectations are closely scrutinized. While J&J MedTech’s revenue fell slightly short of analyst estimates, the overall Q2 results and the upward revision of full-year guidance indicate underlying strength. The market’s reaction, though initially cautious, often recalibrates based on sustained performance and strategic execution.
The $13.1 billion acquisition of Shockwave Medical, though significant, is viewed as a strategic imperative to capture market share in the rapidly growing cardiovascular devices sector. The IVL technology, in particular, addresses a critical need for minimally invasive calcium modification, a common challenge in complex interventional procedures. Analysts are closely monitoring the integration of Shockwave and the realization of its full revenue potential within J&J MedTech.
Similarly, the $14.6 billion acquisition of Intra-Cellular Therapies, which brought Calypta into J&J’s fold, highlights the company’s aggressive approach to strengthening its neuroscience portfolio, a sector with significant unmet medical needs and high growth potential. These strategic acquisitions, coupled with organic growth from established products, form the bedrock of J&J’s long-term value creation strategy.
Broader Implications and Industry Trends
Johnson & Johnson’s Q2 performance provides valuable insights into broader trends within the healthcare and life sciences industries. The sustained growth in MedTech, particularly in specialized areas like cardiovascular intervention, underscores the increasing demand for innovative medical devices that offer improved patient outcomes and procedural efficiency. The company’s strategic acquisitions of Shockwave Medical and its investment in vision care manufacturing exemplify a proactive approach to capitalizing on these market opportunities.
The pharmaceutical segment’s reliance on established, high-value therapies like Darzalex® and Tremfya® highlights the importance of robust R&D pipelines and successful commercialization strategies for biologic drugs and targeted therapies. The continued success of these products, alongside the integration of newly acquired assets like Calypta®, demonstrates J&J’s ability to manage a complex and diverse product portfolio.
The company’s commitment to achieving over $100 billion in annual revenue by 2026 signals its ambition to remain a dominant force in the global healthcare landscape. This target requires sustained innovation, strategic expansion through mergers and acquisitions, and efficient operational management across its three major segments: MedTech, Innovative Medicine, and Consumer Health (though the latter is now largely separated).
In conclusion, Johnson & Johnson’s second-quarter results paint a picture of a resilient and strategically focused healthcare giant. While minor deviations from analyst expectations may trigger short-term market fluctuations, the company’s overall revenue growth, upwardly revised guidance, and significant investments in key growth areas, particularly within its MedTech division, underscore its strong position and promising future outlook. The continued success of its cardiovascular portfolio, fueled by the Shockwave IVL system, alongside its established pharmaceutical drivers and strategic acquisitions, positions J&J to navigate the complexities of the global healthcare market and achieve its ambitious long-term financial goals.
